The interferon-free regimen of ABT-450 with ritonavir ( ABT-450 / r ) , ombitasvir , and dasabuvir with or without ribavirin has shown efficacy in inducing a sustained virologic response in a phase 2 study involving patients with hepatitis C virus ( HCV ) genotype 1 infection .